MindWalk (HYFT) vs. The Competition Head-To-Head Comparison

MindWalk (NASDAQ:HYFT) is one of 458 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its rivals? We will compare MindWalk to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Profitability

This table compares MindWalk and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-145.58%	-56.75%	-31.55%
MindWalk Competitors	-2,662.14%	-363.93%	-42.95%

Earnings & Valuation

This table compares MindWalk and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MindWalk	$17.59 million	-$21.69 million	-2.18
MindWalk Competitors	$432.12 million	-$67.78 million	-10.62

MindWalk’s rivals have higher revenue, but lower earnings than MindWalk. MindWalk is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

6.7% of MindWalk shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for MindWalk and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	0	0	1.50
MindWalk Competitors	4896	9966	15989	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 65.92%. Given MindWalk’s rivals stronger consensus rating and higher possible upside, analysts clearly believe MindWalk has less favorable growth aspects than its rivals.

Volatility & Risk

MindWalk has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, MindWalk’s rivals have a beta of 5.42, meaning that their average stock price is 442% more volatile than the S&P 500.

Summary

MindWalk rivals beat MindWalk on 8 of the 13 factors compared.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.